This site uses cookies that are essential for the operation of this site. We use additional cookies to support optional features of the site or to gather anonymous usage statistics for the improvement of this site. More information
By continuing to browse the site you are agreeing to our use of cookies.

EASING THE EFFECTS
OF MULTIPLE DAILY
INJECTIONS

EDUCATION AND INNOVATION TO OVERCOME
THE PAIN AND ANXIETY ASSOCIATED WITH MULTIPLE DAILY INJECTIONS

MDI - MULTIPLE DAILY INJECTIONS FOR DIABETES PATIENTS

Multiple Daily Injections (MDI) is the first line of diabetes treatment in Europe. It is defined as: the administration of 3/more insulin injections/day. This includes one injection of long-acting insulin (24h hours active) in the evening and an injection of rapid or short-acting insulin before each meal.

On this regimen, the physiologic replacement of mealtime insulin secretion is administered three times a day using rapid or short-acting insulin. These injections are given before meals and are typically adjusted to match food intake using an insulin-to-carbohydrate ratio.

When compared to regular insulin, rapid-acting insulin is typically preferred because it provides better physiologic insulin coverage for meals and more closely matches the glucose level rise that occurs in response to meals. The peak action time of rapid-acting insulin occurs at approximately 1-1.5 hours after administration. This correlates well with the digestion of most meals.

KNOW MORE ON NICE GUIDANCE ALGORITMY

Continuous Glucose Monitoring IPro2 device - Providing more accurate data

Using the blood glucose (BG) method only, you may miss your patients’ hypoglycaemia or hyperglycaemia events as BG only provides a momentary reading . By using iPro2 - the only available professional Continuous Glucose Monitoring (CGM) device designed for the masked collection of glucose level data - you will benefit from more precise insights into your patients’ glycaemic profile.

LEARN MORE

ALTERNATIVES TO MULTIPLE DAILY INJECTIONS (MDI) DIABETES TREATMENT: INSULIN PUMP THERAPY

This therapy mimics the functions of a normal pancreas more closely and replaces the need for frequent insulin injections by delivering precise doses of rapid-acting insulin.

Even though long acting insulins are designed to last 24 hours without a pronounced peak, it does not always last this long in many individuals, and in others it may last longer.

Some diabetes patients must divide their long acting insulin into two injections, with half of the dose administered in the morning and the other half administered in the evening.

The acidic PH of long acting insulin can result in a slight burning sensation when it is administered.

SENSOR AUGMENTED THERAPY FOR DIABETES PATIENTS

There are three main components to Sensor Augmented Therapy:

  1. A compatible Medtronic MiniMed Insulin Pump,
  2. A Continuous Glucose Monitoring (CGM) system
  3. Therapy management software.

One of the most advanced system on the market as of November 2015; the MiniMed® 640G Insulin Pump System with SmartGuard™ features technology that closely mimics the way a healthy pancreas delivers basal insulin to the body – giving your patients better control of their diabetes.

LEARN MORE

I-port Advance insulin device offers a life with fewer injections for diabetes patients

Do you have patients who miss their regular injections because of needle phobia? i-port Advance is a new injection port designed to overcome the pain and anxiety associated with injections.
(Components sold separately. Automated insulin delivery is made possible through combining Medtronic insulin pump and continuous glucose monitoring technology).

LEARN MORE

Recommended Information

LEAVE A FEEDBACK